Jakafi 10mg Tablets are an advanced prescription medicine containing Ruxolitinib 10mg, an oral Janus Kinase (JAK1 and JAK2) inhibitor used for the treatment of specific blood disorders and certain hematological cancers. This medicine is prescribed by hematologists and oncologists to help manage diseases that involve abnormal blood cell production and chronic inflammation.
Jakafi is widely recognized for its effectiveness in treating Myelofibrosis (MF), Polycythemia Vera (PV), and Graft-versus-Host Disease (GVHD). These conditions can significantly affect a patient's quality of life, causing symptoms such as fatigue, weakness, enlarged spleen, severe itching, night sweats, bone pain, weight loss, and other complications. Jakafi works by targeting abnormal signaling pathways responsible for these symptoms, helping patients achieve better disease control under medical supervision.
As an imported oncology medicine available in Pakistan, Jakafi 10mg is recommended only after a thorough medical evaluation. It should never be started, stopped, or adjusted without the advice of a qualified healthcare professional.
Jakafi is the brand name of Ruxolitinib, a targeted therapy belonging to the class of medicines known as Janus Kinase (JAK) inhibitors.
Unlike conventional chemotherapy, which affects both healthy and cancerous cells, Ruxolitinib specifically blocks overactive JAK1 and JAK2 enzymes. These enzymes play a major role in the production of blood cells and inflammatory responses. When these pathways become overactive, they contribute to the development and progression of disorders such as Myelofibrosis and Polycythemia Vera.
By reducing abnormal JAK signaling, Jakafi helps control disease activity, reduce inflammation, improve blood cell regulation, and relieve many of the symptoms associated with these conditions.
Doctors may prescribe Jakafi 10mg Tablets for:
Your doctor may also prescribe this medicine for other approved or clinically appropriate indications based on your individual medical condition.
Treatment with Jakafi may help:
Jakafi 10mg Tablets contain Ruxolitinib, a targeted medicine that belongs to a group of drugs known as Janus Kinase (JAK) inhibitors. These medicines work differently from traditional chemotherapy. Instead of attacking rapidly dividing cells, Jakafi targets specific enzymes called JAK1 and JAK2, which are involved in blood cell production and immune system signaling.
In diseases such as Myelofibrosis (MF) and Polycythemia Vera (PV), these signaling pathways become overactive. This overactivity causes the body to produce abnormal blood cells and inflammatory proteins, leading to enlarged spleen, fatigue, bone pain, fever, weight loss, and other serious symptoms.
By blocking JAK1 and JAK2 activity, Jakafi helps normalize these abnormal signals. As a result, many patients experience reduced spleen size, improved blood circulation, relief from disease-related symptoms, and a better quality of life.
Unlike many conventional cancer treatments, Jakafi is designed to target specific disease mechanisms, making it an important option for selected patients with blood disorders.
Jakafi should only be used by patients who have been diagnosed by a qualified hematologist or oncologist. It is not intended for self-medication or routine use.
Doctors may prescribe Jakafi for adults diagnosed with:
The decision to start treatment depends on several factors, including blood counts, liver and kidney function, previous treatments, and the patient's overall health.
Store Jakafi Tablets:
Customers Reviews For Jakafi 10mg Tablets (Ruxolitinib) in Pakistan